CDC's RSV vaccine recommendations from Pfizer and GSK face review by HHS advisor William "Reyn" Archer III. Read more here.

An FDA panel of experts has recommended approval of Pfizer’s respiratory syncytial virus (RSV) vaccine in a pair of ... s RSVPreF3 jab will come under the scrutiny of the VRBPAC later today ...

The advisory panel to the Centers for Disease Control and Prevention had made recommendations regarding the use of separate ...

GSK's vaccine against respiratory syncytial virus (RSV) is one of ... with the final results of Pfizer's study and as the data from both studies is subjected to scrutiny. The two companies say ...

ACIP is recommending that adults aged 50 to 59 years who are at increased risk for severe RSV disease receive a single dose of an RSV vaccine.

Far fewer babies had severe cases of the respiratory illness RSV, in a winter in which a new monoclonal and vaccine became ...

Additional data required by the FDA are the latest evidence of what one analyst described as a “higher bar” for vaccines.

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) has issued new separate recommendations supporting expanded use of Pfizer’s respiratory syncytial ...

Pfizer recently received a CDC recommendation for wider use of its RSV vaccine, ABRYSVO, in adults aged 50-59 at increased risk. Despite this positive development, Pfizer's shares saw a 2% decline ...